| abstract |
The present invention relates to a GATA-3 inhibitor used in the treatment of Th2-type asthma, in particular, (i) a blood eosinophil count of 3% or more, specifically 4% or more, more particularly 5% or more. And / or (ii) characterized by a blood eosinophil count of 350 × 10 6 / L or higher, in particular 450 × 10 6 / L or higher, and / or (iii) a breath nitric oxide concentration of 40 ppb or higher. The present invention relates to a GATA-3-directed DNAzyme for use in the treatment of patients suffering from allergic asthma. |